BEDFORD, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it will participate in two investor conferences in September: Baird 2024 Global Healthcare Conference Fireside Chat Date: Tuesday, September 10, 2024 Presentation Time: 12:50 PM ET ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Bill Slattery - VP, IR Pravin Dugel - Executive Chairman, President, CEO Conference Call Participants Tazeen Ahmad - Bank of America Merrill Lynch Biren Amin - Piper Sandler Tara Bancroft - TD Cowen Colleen Kusy - Baird Kelly Shi - Jefferies Sean McCutcheon - Raymond James Yi Chen - H.C. Wainwright & Co. Operator Good morning, and welcome to the Ocular Therapeutix second-quarter 2024 earnin ...

Shares of Ocular Therapeutix (OCUL) have gained 5.7% over the past four weeks to close the last trading session at $8.03, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.89 indicates a potential upside of 85.4%. The mean estimate comprises nine short-term price targets with a standard deviation of $3.30. While the lowest estimate of $11 indicates a 37% increase from the curr ...

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -9.09%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.18 per share when it actually produced a loss of $0.24, delivering a surprise of -33.33%. Over the last four quarters, the ...

Table of Contents Common Stock, $0.0001 par value per share OCUL The Nasdaq Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |------------------------------------------------------------------------------- ...

Exhibit 99.1 Ocular Therapeutix™ Reports Second Quarter 2024 Results SOL-R AXPAXLI™ Repeat Dosing Study in Wet AMD Acceptable to FDA as Registrational Trial Enrollment in SOL-1 Continues to Accelerate and SOL-R Actively Enrolling Patients Cash Balance of $459.7M as of June 30, 2024, Expected to Fund Operations into 2028 Ocular Will Host a Q2 2024 Conference Call and Webcast Today, August 7th, at 8:00 AM ET BEDFORD, MA, August 7, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the ...

SOL-R AXPAXLI™ Repeat Dosing Study in Wet AMD Acceptable to FDA as Registrational Trial Enrollment in SOL-1 Continues to Accelerate and SOL-R Actively Enrolling Patients Cash Balance of $459.7M as of June 30, 2024, Expected to Fund Operations into 2028 Ocular Will Host a Q2 2024 Conference Call and Webcast Today, August 7th, at 8:00 AM ET BEDFORD, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to improving visi ...

BEDFORD, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) ("Ocular"), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it plans to host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 AM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2024. The ...

SOL-R evaluates repeat AXPAXLI™ dosing for wet age-related macular degeneration (wet AMD) SOL-R is a global, 825-patient, non-inferiority study evaluating repeat dosing of AXPAXLI every six months (Q6M) compared to 2 mg aflibercept, dosed every eight weeks (Q8W) in patients with wet AMD. A third arm evaluating 8 mg aflibercept dosed Q6M is incorporated to ensure the study is adequately masked. The trial is evaluating AXPAXLI versus the current standard of care under the "real world" requirements of a repeat ...

BEDFORD, Mass., July 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that a late-breaking abstract related to the Phase 1 HELIOS study of AXPAXLI (axitinib intravitreal imp ...